ARNA Arena Pharmaceuticals Inc.

41.09
-1.47  -3%
Previous Close 42.56
Open 42.28
Price To Book 3.82
Market Cap 2030111113
Shares 49,406,452
Volume 465,493
Short Ratio
Av. Daily Volume 669,128

SEC filingsSee all SEC filings

  1. 8-K - Current report 181225160
  2. 8-K - Current report 181186003
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176073
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169798
  5. 8-K - Current report 181166241

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Etrasimod
Primary biliary cholangitis (PBC)
Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2 data released September 24, 2018.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data released March 19, 2018 - primary and secondary endpoints met.
Etrasimod
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. Is Arena Pharmaceuticals, Inc. (ARNA) A Good Stock To Buy?
  2. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings
  3. What Did Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) CEO Take Home Last Year?
  4. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics
  5. Research Report Identifies Cheniere Energy Partners, LP, Arena Pharmaceuticals, Geron, Keysight Technologies, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Casella Waste with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  6. Analysts: Why United Therapeutics has had a streak of licensing deals
  7. A Look at Amarin Corporation’s Stock Performance Year-to-Date
  8. Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs
  9. 2 New Small Cap ETFs on the Block
  10. Opioid Alternatives Could Make Investors Major Gains
  11. Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal
  12. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
  13. Edited Transcript of ARNA earnings conference call or presentation 7-Nov-18 9:30pm GMT
  14. My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy
  15. Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
  16. Today’s Research Reports on Stocks to Watch: Arena Pharmaceuticals and Sonoma Pharmaceuticals
  17. Why Arena Pharmaceuticals, Smart & Final Stores, and Tilray Jumped Today
  18. Stocks on the move: JP Morgan shares increase as Walmart beat estimates but shy on revenue
  19. Why Arena Pharmaceuticals Stock Is Soaring Today
  20. Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today

SEC Filings

  1. 8-K - Current report 181225160
  2. 8-K - Current report 181186003
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176073
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169798
  5. 8-K - Current report 181166241
  6. 8-K - Current report 181106933
  7. 8-K - Current report 181101274
  8. 8-K - Current report 181083554
  9. UPLOAD [Cover] - SEC-generated letter
  10. CORRESP [Cover] - Correspondence